Photo via CNBC
Vivani Medical is pursuing a novel delivery method for weight loss management through an implantable device containing semaglutide, the same pharmaceutical compound used in Novo Nordisk's popular obesity treatment Wegovy and its diabetes counterpart Ozempic. The implant approach represents an emerging strategy to address one of the persistent challenges in weight loss treatment: maintaining results after patients cease medication.
The company's implant-based approach distinguishes itself from existing injection-based therapies by offering patients a less frequent dosing regimen. According to the company's development strategy, the subcutaneous implant aims to provide continuous, controlled drug delivery over an extended period, potentially improving patient adherence and reducing the burden of regular injections that characterize current GLP-1 receptor agonist treatments.
As the market for GLP-1 therapies expands rapidly, developers are racing to improve on established delivery mechanisms. Vivani Medical's implantable technology demonstrates the broader industry trend toward innovation in how GLP-1 drugs reach patients, with the goal of simplifying treatment regimens while maintaining the clinical benefits that have made these medications central to contemporary obesity and diabetes management.
